Literature DB >> 22918258

ICU-acquired weakness: mechanisms of disability.

Claudia C Dos Santos1, Jane Batt.   

Abstract

PURPOSE OF REVIEW: ICU-acquired weakness (ICUAW) is now recognized as a major complication of critical illness. There is no doubt that ICUAW is prevalent - some might argue ubiquitous - after critical illness, but its true role, the interaction with preexisting nerve and muscle lesions as well as its contribution to long-term functional disability, remains to be elucidated. RECENT
FINDINGS: In this article, we review the current state-of-the-art of the basic pathophysiology of nerve and muscle weakness after critical illness and explore the current literature on ICUAW with a special emphasis on the most important mechanisms of weakness.
SUMMARY: Variable contributions of structural and functional changes likely contribute to both early and late myopathy and neuropathy, although the specifics of the temporality of both processes, and the influence patient comorbidities, age, and nature of the ICU insult have on them, remain to be determined.

Entities:  

Mesh:

Year:  2012        PMID: 22918258     DOI: 10.1097/MCC.0b013e328357cb5e

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  4 in total

Review 1.  Strategies to combat chronic critical illness.

Authors:  Jennifer M Maguire; Shannon S Carson
Journal:  Curr Opin Crit Care       Date:  2013-10       Impact factor: 3.687

Review 2.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

3.  Intensive care unit acquired weakness in children: Critical illness polyneuropathy and myopathy.

Authors:  Vinay Kukreti; Mosharraf Shamim; Praveen Khilnani
Journal:  Indian J Crit Care Med       Date:  2014-02

4.  Upregulation of Heme Oxygenase-1 by Hemin Alleviates Sepsis-Induced Muscle Wasting in Mice.

Authors:  Xiongwei Yu; Wenjun Han; Changli Wang; Daming Sui; Jinjun Bian; Lulong Bo; Xiaoming Deng
Journal:  Oxid Med Cell Longev       Date:  2018-11-08       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.